BharatNotes What Are Intellectual Property Rights?
Intellectual Property Rights (IPR) are legal rights granted to creators and inventors to protect their creations of the mind — inventions, literary and artistic works, designs, symbols, names, and images. IPR provides exclusive rights for a limited period, balancing the interests of creators (who need incentives to innovate) with the public interest (which benefits from the diffusion of knowledge).
Types of Intellectual Property
| Type | What It Protects | Duration (India) | Governing Law (India) |
|---|---|---|---|
| Patents | Inventions — new, inventive, and industrially applicable products or processes | 20 years from filing date | Patents Act, 1970 (amended 2005) |
| Copyrights | Literary, dramatic, musical, and artistic works; cinematograph films; sound recordings | Lifetime of author + 60 years (for literary works); 60 years from publication (for films, sound recordings) | Copyright Act, 1957 |
| Trademarks | Distinctive signs (words, logos, symbols, sounds) that distinguish goods/services | 10 years, renewable indefinitely | Trade Marks Act, 1999 |
| Industrial designs | Ornamental or aesthetic aspects of an article — shape, pattern, configuration, colour | 10 years, extendable by 5 years (total 15 years) | Designs Act, 2000 |
| Geographical Indications (GI) | Products originating from a specific geographical location with qualities attributable to that origin | 10 years, renewable indefinitely | Geographical Indications of Goods Act, 1999 |
| Trade secrets | Confidential business information — formulas, processes, customer lists | No registration; protected as long as secrecy is maintained | No specific legislation — protected under contract law, common law, and the Information Technology Act |
| Plant varieties | New plant varieties developed through breeding | 6–18 years depending on the type of plant | Protection of Plant Varieties and Farmers' Rights Act, 2001 |
| Semiconductor layout designs | Layout designs of integrated circuits | 10 years from filing | Semiconductor Integrated Circuits Layout-Design Act, 2000 |
For Mains: IPR is fundamentally about balance — between incentivising innovation and ensuring public access to knowledge. In the Indian context, this balance is particularly important in pharmaceuticals (patent protection vs affordable medicines), agriculture (plant variety protection vs farmers' rights), and traditional knowledge (protecting indigenous knowledge from biopiracy).
Patents — The Central IPR in Science & Technology
Patents Act, 1970 — Key Features
| Feature | Detail |
|---|---|
| Enacted | 1970; came into effect on 20 April 1972 |
| Major amendment | 2005 amendment — introduced product patents for all fields of technology (including pharmaceuticals and agrochemicals), bringing India into compliance with TRIPS |
| Pre-2005 regime | Only process patents (not product patents) were granted for food, medicines, and chemicals — this enabled India's generic pharmaceutical industry to grow |
| Patent term | 20 years from the date of filing |
| Patentability criteria | Novelty + Inventive step (non-obvious) + Industrial applicability |
| Controller General | The Controller General of Patents, Designs and Trademarks administers the patent system through patent offices in Kolkata (head office), Mumbai, Delhi, and Chennai |
What Is NOT Patentable in India (Key Exclusions — Section 3)
| Section | Exclusion |
|---|---|
| 3(b) | Inventions whose use would be contrary to public order or morality, or which cause serious harm to human, animal, or plant life or the environment |
| 3(c) | Discovery of a scientific principle or formulation of an abstract theory |
| 3(d) | Mere discovery of a new form of a known substance unless it results in enhanced efficacy — the "anti-evergreening" provision |
| 3(e) | Substance obtained by a mere admixture resulting only in aggregation of properties |
| 3(h) | Method of agriculture or horticulture |
| 3(i) | Any process for the medicinal, surgical, curative, prophylactic, diagnostic, therapeutic or other treatment of human beings or animals |
| 3(j) | Plants and animals in whole or any part thereof (other than microorganisms); essentially biological processes for production or propagation of plants and animals |
| 3(k) | Mathematical or business methods, computer programmes per se, algorithms |
Section 3(d) — The Anti-Evergreening Provision
This is India's most internationally significant patent provision. It prevents "evergreening" — the practice of making minor modifications to existing drugs (changing salt form, crystal structure, etc.) to extend patent protection beyond the original 20 years.
Full text of the key portion: The mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance, or the mere discovery of any new property or new use for a known substance, is not patentable.
Clarification: Salts, esters, ethers, polymorphs, metabolites, pure form, particle size, isomers, mixtures of isomers, complexes, combinations, and other derivatives of known substances shall be considered the same substance, unless they differ significantly in properties with regard to efficacy.
For Prelims: Section 3(d) of the Patents Act prevents evergreening. It was the central legal provision in the landmark Novartis vs Union of India case (2013). India does not grant patents for mathematical methods, business methods, or computer programmes per se.
Landmark Patent Cases in India
Novartis AG vs Union of India (2013) — The Glivec Case
| Aspect | Detail |
|---|---|
| Drug | Glivec (Gleevec) — imatinib mesylate, a cancer drug used for chronic myeloid leukaemia (CML) |
| Novartis' claim | Patent for the beta-crystalline form of imatinib mesylate — Novartis argued this was a new and improved form of the drug |
| India's rejection | Madras Patent Office (2006) rejected the application under Section 3(d) — the new form did not show enhanced therapeutic efficacy |
| Supreme Court judgment | 1 April 2013 — the Court unanimously upheld the rejection, ruling that "efficacy" in Section 3(d) means therapeutic efficacy for pharmaceutical substances, not mere physical properties (solubility, stability, bioavailability) |
| Key quote | Physical properties like stability, solubility, and hygroscopicity may be advantageous but they do not directly make the drug better at curing disease |
| Impact on drug pricing | After the ruling, generic versions of imatinib were available at approximately USD 88 per month, compared to Novartis' price of approximately USD 2,200 per month |
| Global significance | The case established India as a defender of affordable medicines and validated the use of TRIPS flexibilities by developing countries |
Natco Pharma vs Bayer Corporation (2012) — India's First Compulsory Licence
| Aspect | Detail |
|---|---|
| Drug | Sorafenib tosylate (brand name Nexavar) — used for liver and kidney cancer |
| Patent holder | Bayer Corporation |
| Applicant | Natco Pharma Ltd |
| Decision | 12 March 2012 — the Controller General of Patents granted India's first (and so far only) compulsory licence under Section 84(1) of the Patents Act |
| Three grounds (Section 84) | (1) Reasonable requirements of the public not satisfied; (2) Drug not available at reasonably affordable price — Bayer charged Rs 2.8 lakh for a month's supply; (3) Patented invention not worked (manufactured) in India |
| Terms | Natco allowed to sell Nexavar at Rs 8,800 per month (compared to Bayer's Rs 2,80,000); Natco to pay Bayer a 6% royalty on net sales |
| Upheld | Appellate Board (IPAB) upheld the decision in 2013; Bayer's appeal dismissed |
For Mains: The Nexavar compulsory licence case demonstrates the use of TRIPS flexibilities to ensure access to affordable medicines. Section 84 of the Patents Act allows compulsory licensing on three grounds — unmet public need, unaffordable pricing, and non-working of the patent in India. Critics argue that compulsory licensing discourages pharmaceutical R&D investment in India; supporters argue it is essential to prevent patent monopolies from pricing out life-saving treatments.
TRIPS Agreement
Overview
| Feature | Detail |
|---|---|
| Full name | Agreement on Trade-Related Aspects of Intellectual Property Rights |
| Adopted | 1994 as part of the Uruguay Round of GATT negotiations; came into effect on 1 January 1995 with the establishment of the WTO |
| Administered by | World Trade Organization (WTO) |
| Significance | The first comprehensive multilateral agreement on intellectual property — sets minimum standards for IP protection that all WTO members must comply with |
| India's compliance | India amended the Patents Act in 2005 to introduce product patents for pharmaceuticals — the key requirement for TRIPS compliance |
Key Provisions of TRIPS
| Provision | Description |
|---|---|
| Minimum standards | All WTO members must provide minimum levels of IP protection for patents (20 years), copyrights (50 years after death), trademarks, GIs, industrial designs, etc. |
| National treatment | Each WTO member must give nationals of other WTO members treatment no less favourable than its own nationals |
| Most Favoured Nation (MFN) | Any advantage, favour, privilege or immunity granted to nationals of one country must be extended to nationals of all WTO members |
| Enforcement | Members must provide effective enforcement mechanisms — judicial and administrative procedures, border measures, criminal sanctions |
| Dispute settlement | IP disputes between WTO members can be brought before the WTO Dispute Settlement Body |
TRIPS Flexibilities
| Flexibility | Description |
|---|---|
| Compulsory licensing | Members can issue compulsory licences allowing production of patented products without the patent holder's consent, subject to certain conditions (Article 31) |
| Parallel imports | Members can import patented products from any country where they are sold at a lower price |
| Government use | Governments can use patented inventions for public, non-commercial purposes |
| Transition periods | Developing countries were given transition periods to comply (India used the full period until 2005) |
| Section 3(d) type provisions | TRIPS does not prohibit higher patentability standards than the minimum — India's Section 3(d) is TRIPS-compliant |
The Doha Declaration on TRIPS and Public Health (2001)
| Feature | Detail |
|---|---|
| Adopted | 14 November 2001, at the WTO Ministerial Conference in Doha, Qatar |
| Core statement | "The TRIPS Agreement does not and should not prevent members from taking measures to protect public health" |
| Key affirmations | Members have the right to grant compulsory licences; each member has the right to determine what constitutes a national emergency; the right to establish exhaustion regimes (parallel imports) without challenge |
| Paragraph 6 solution | Addressed the problem of countries with insufficient manufacturing capacity — led to the TRIPS amendment (Article 31bis, effective 2017) allowing export of generics under compulsory licence to countries that cannot manufacture them |
| Significance | Reaffirmed the primacy of public health over patent protection and legitimised the use of TRIPS flexibilities by developing countries |
For Prelims: The Doha Declaration (2001) reaffirmed the right of WTO members to use TRIPS flexibilities (compulsory licensing, parallel imports) for public health. Article 31bis (effective 2017) was the amendment to TRIPS allowing export of generic drugs under compulsory licence to countries without manufacturing capacity.
Geographical Indications (GI Tags)
GI Framework in India
| Feature | Detail |
|---|---|
| Governing law | Geographical Indications of Goods (Registration and Protection) Act, 1999 |
| Came into effect | 15 September 2003 |
| Registrar | Geographical Indications Registry, Chennai |
| Duration | 10 years, renewable indefinitely |
| First GI tag in India | Darjeeling Tea (2004-05) — from West Bengal |
| Total GI tags registered | 658 as of early 2026 |
| Categories | Agriculture (Basmati rice, Alphonso mango), handicrafts (Pashmina, Kancheepuram silk), foodstuffs (Ratlami sev, Hyderabadi Haleem), manufactured goods (Mysore Agarbatti), natural goods (Makrana marble) |
Notable GI-Tagged Products
| Product | State | Significance |
|---|---|---|
| Darjeeling Tea | West Bengal | First GI tag in India; internationally protected — the word mark and logo are recognised globally |
| Basmati Rice | Multiple states (Punjab, Haryana, UP, Uttarakhand, HP, J&K, Delhi) | Contested GI — Pakistan also claims Basmati; India has sought GI protection in the EU |
| Pashmina | Jammu & Kashmir | Premium textile; GI protection helps distinguish genuine Pashmina from machine-made imitations |
| Mysore Silk | Karnataka | Protected against misuse of the "Mysore Silk" name |
| Tirupati Laddu | Andhra Pradesh | One of India's most distinctive food products with GI protection |
| Madhubani Paintings | Bihar | Traditional art form with GI protection |
| Kancheepuram Silk | Tamil Nadu | High-value silk textile with centuries of heritage |
GI Tags vs Patents vs Trademarks
| Feature | GI Tag | Patent | Trademark |
|---|---|---|---|
| Protects | Origin-linked quality and reputation | Inventions | Brand identity |
| Ownership | Community/collective (producers in the region) | Individual/company | Individual/company |
| Duration | 10 years, renewable indefinitely | 20 years (non-renewable) | 10 years, renewable indefinitely |
| Territorial | Tied to a specific geographical area | Territorial (country where filed) | Territorial but can be extended |
| Can be sold/transferred | No — cannot be bought, sold, or licensed | Yes — can be assigned, licensed | Yes — can be assigned, licensed |
For Prelims: India has 658 registered GI tags as of early 2026. The first GI tag was Darjeeling Tea (2004-05). GI tags are registered at the Geographical Indications Registry in Chennai. Unlike patents, GI tags are community-owned and cannot be sold or transferred.
Traditional Knowledge Protection
The Biopiracy Problem
Biopiracy refers to the appropriation of traditional knowledge, genetic resources, or biological materials by external parties (typically corporations or researchers from developed countries) through the patent system, without authorisation from or compensation to the communities that developed and preserved that knowledge.
Landmark Biopiracy Cases Involving India
| Case | Year | Details |
|---|---|---|
| Turmeric patent | 1995–1997 | Two scientists at the University of Mississippi obtained a US patent for wound-healing properties of turmeric. India's CSIR challenged the patent, presenting prior art from ancient Sanskrit texts. The US Patent and Trademark Office (USPTO) revoked the patent in 1997 — a landmark victory |
| Neem patent | 1994–2005 | The European Patent Office (EPO) granted W.R. Grace & Co. a patent for a neem-based antifungal product. After a decade-long legal battle, the EPO revoked the patent in 2005, accepting that the use was part of traditional knowledge |
| Basmati rice | 1997 | RiceTec Inc. (US) obtained a patent for "Basmati rice lines and grains." India challenged several claims, and the USPTO narrowed the patent significantly — removing claims on the name "Basmati" |
Traditional Knowledge Digital Library (TKDL)
| Feature | Detail |
|---|---|
| Established | 2001 — collaboration between CSIR and the then Ministry of Health and Family Welfare |
| Purpose | Prevent the granting of wrong patents based on traditional knowledge by making India's traditional knowledge available to patent examiners worldwide in a format and language they can use |
| Content | Documentation of over 4.5 lakh formulations from traditional Indian medicine systems — Ayurveda, Unani, Siddha, Yoga |
| Languages | Translated into 5 international languages (English, French, German, Spanish, Japanese) using a specially developed Traditional Knowledge Resource Classification (TKRC) |
| Access agreements | TKDL has signed agreements with major patent offices — EPO, USPTO, UKPTO, and others — granting access for prior art searches |
| Impact | Led to the withdrawal or rejection of over 300 patent applications worldwide that attempted to claim traditional Indian knowledge as novel |
For Mains: India's TKDL is a defensive protection mechanism — it prevents others from patenting India's traditional knowledge, but it does not generate economic returns for traditional knowledge holders. India needs complementary "positive protection" — legal mechanisms that enable traditional knowledge holders to commercially exploit their knowledge and receive benefits. The Biological Diversity Act, 2002 provides for benefit-sharing but enforcement has been weak.
National Intellectual Property Rights Policy, 2016
| Feature | Detail |
|---|---|
| Approved | 12 May 2016 by the Union Cabinet |
| Nodal department | Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry |
| Objectives | Creative India; Innovative India — foster innovation and creativity across all sectors |
| Key pillars | (1) IP awareness and outreach, (2) Generation of IPRs, (3) Legal and legislative framework, (4) IP administration and management, (5) Commercialisation of IP, (6) Enforcement and adjudication, (7) Human capital development |
| Cell for IPR Promotion and Management (CIPAM) | Established under DPIIT to implement the policy; conducts IP awareness programmes, handles anti-piracy activities |
| IP Facilitation Centre | Provides free facilitation services for startups under the Startup India programme |
India's Patent Filing Performance
| Metric | Data |
|---|---|
| Global ranking | India became the world's 6th largest patent filer in 2024 (WIPO Intellectual Property Indicators 2025) |
| Total filings in 2024 | Over 63,000 patent applications |
| Resident share | For the first time, over 55% of India's patent applications were filed by domestic applicants (2023) — previously, foreign applicants dominated |
| Growth trend | Eighth consecutive year of growth; 16.5% increase in 2024; third consecutive year of double-digit growth |
| Top 10 across all categories | For the first time, India ranked in the top 10 globally across patents, trademarks, and industrial designs |
For Prelims: India's National IPR Policy was approved in 2016. India became the 6th largest patent filer globally in 2024 (WIPO report). Over 55% of India's patent applications are now from domestic applicants — a significant shift from the previous dominance of foreign filers.
Plant Variety Protection and Farmers' Rights
Protection of Plant Varieties and Farmers' Rights Act, 2001
| Feature | Detail |
|---|---|
| Enacted | 2001; Protection of Plant Varieties and Farmers' Rights Authority (PPVFRA) established in 2005 |
| Purpose | Provides IP protection for plant varieties developed through breeding while protecting the rights of farmers |
| Types of registration | New variety, Extant variety, Essentially derived variety, Farmers' variety |
| Duration | 15 years for crops (18 years for trees and vines) from date of registration |
| Farmers' rights (Section 39) | Farmers can save, use, sow, re-sow, exchange, share, and sell farm produce including seed of a protected variety — but cannot sell branded seed |
| Benefit sharing | Breeders must share benefits with farming communities that contributed to the development of genetic resources |
| Unique feature | India's PVPFRA is unique globally because it includes farmers' rights alongside breeders' rights — unlike UPOV (International Union for the Protection of New Varieties of Plants) which focuses solely on breeders' rights |
For Mains: India's PVPFRA (2001) is a sui generis (unique) system as permitted under TRIPS Article 27.3(b). It balances breeders' rights with farmers' rights — a critically important balance in a country where agriculture is the primary livelihood for hundreds of millions. India chose not to join UPOV precisely because UPOV restricts farmers' rights to save and exchange seeds.
Copyright in the Digital Age
Key Challenges
| Challenge | Detail |
|---|---|
| Digital piracy | Unauthorised copying and distribution of copyrighted content (movies, music, software, books) has been vastly amplified by the internet |
| Fair use vs piracy | The boundary between legitimate fair use (research, criticism, education) and piracy is increasingly blurred in the digital context |
| AI-generated content | Who owns the copyright on content created by AI? Can AI be an "author" under copyright law? Current Indian law requires a human author |
| Open access | The movement towards open access to scientific research (particularly publicly funded research) challenges traditional journal publishing models |
| DRM and access | Digital Rights Management (DRM) technologies can restrict legitimate uses (e.g., a visually impaired person using text-to-speech on an e-book) |
| Platform liability | Should platforms (YouTube, social media) be liable for copyrighted content uploaded by users? India's IT Act and Copyright Act create a "safe harbour" with conditions |
India's Copyright Act, 1957 (Key Features)
| Feature | Detail |
|---|---|
| Scope | Protects literary, dramatic, musical, and artistic works; cinematograph films; sound recordings |
| Duration | Author's lifetime + 60 years for literary, dramatic, musical, and artistic works |
| Fair dealing | Section 52 provides a list of acts that do not constitute infringement — private use, research, criticism, review, reporting current events, education |
| Copyright Board | Previously, Copyright Board handled disputes; now transferred to the Appellate Board/Commercial Courts |
| Marrakesh Treaty | India ratified the Marrakesh Treaty (2014) which facilitates access to published works for persons who are blind, visually impaired, or otherwise print-disabled |
Evergreening and Data Exclusivity
Evergreening
| Aspect | Detail |
|---|---|
| Definition | Strategy used by pharmaceutical companies to extend patent protection beyond 20 years by obtaining new patents on minor modifications of existing drugs — new formulations, dosage forms, salt forms, combinations |
| How it works | When the original patent on a blockbuster drug is about to expire, the company files patents on modifications, effectively blocking generic competition |
| India's response | Section 3(d) of the Patents Act specifically targets evergreening — it prevents patenting of new forms unless enhanced therapeutic efficacy is demonstrated |
| Global debate | Pharmaceutical companies argue modifications genuinely improve drugs; critics argue it is a strategy to maintain monopoly pricing |
Data Exclusivity
| Aspect | Detail |
|---|---|
| Definition | A period during which regulatory authorities cannot rely on the originator's clinical trial data to approve generic versions — even if the patent has expired or no patent exists |
| Current Indian position | India does NOT provide data exclusivity — generic manufacturers can rely on the originator's data for regulatory approval (bioequivalence studies are sufficient) |
| Pressure on India | US and EU have pushed India to adopt data exclusivity through bilateral trade agreements; the US Special 301 Report has placed India on the "Priority Watch List" |
| Impact if adopted | Data exclusivity would delay generic entry even for drugs not protected by patents — increasing medicine prices significantly |
| India's defence | Data exclusivity is not required by TRIPS; adopting it would undermine India's generic pharmaceutical industry and increase medicine prices for developing countries |
For Mains: Data exclusivity is distinct from patent protection. Even when a drug has no patent (or the patent has been invalidated under Section 3(d)), data exclusivity would prevent generic competition for several years. India's refusal to grant data exclusivity is as important as Section 3(d) in maintaining affordable medicine access. The US has consistently pressured India on this issue through the Special 301 Report and bilateral negotiations.
Recent Developments (2024–2026)
India Patent Filings — 6th Globally, 110,375 Applications FY25, 44% Growth in 5 Years
India's intellectual property system reached new milestones in 2024–2025. Patent applications filed in India reached 110,375 in FY 2024–25, up from 58,503 in FY 2020–21 — a 180% increase over five years. India ranked 6th globally in patent filings in 2024 with 63,000+ patents (WIPO World Intellectual Property Indicators 2025), with more than 55% filed by Indian residents — a significant shift from earlier decades when foreign applicants dominated. India achieved the sixth consecutive year of double-digit patent growth (+19.1% in 2024).
Overall IP filings (patents, trademarks, GI, designs, copyright) reached 6,89,991 in FY 2024–25, a 44% increase from 4,77,533 in FY 2020–21. The most dramatic growth was in Geographical Indications (GI) registrations — a 380% increase over five years, with India registering over 600 GI products as of March 2024, led by Uttar Pradesh (69 products) followed by Karnataka and Tamil Nadu. Designs grew 266% and copyright registrations 83% in the same period.
UPSC angle: India 6th in global patents (63,000+ in 2024), 110,375 applications FY25, 180% growth in 5 years, 600+ GI products (380% growth), and IP filings up 44% overall are Prelims and Mains GS-3 content on India's IPR ecosystem.
GI Tags and Traditional Knowledge — Expansion and TKDL Effectiveness 2024
India's Geographical Indication (GI) tag system, governed by the Geographical Indications of Goods (Registration and Protection) Act, 1999, reached 600+ registered GI products by March 2024. Recent notable GI registrations include Muga Silk of Assam, Kondapalli Toys of Andhra Pradesh, Tirur Betel Leaf of Kerala, and Banaras Chikan Embroidery. The GI tag provides legal protection against imitation and enables premium pricing for artisan products — with Darjeeling Tea's GI (India's first, 2004) demonstrating export value enhancement.
The Traditional Knowledge Digital Library (TKDL), maintained by CSIR and the Ministry of AYUSH, compiled 0.34 million traditional medicinal formulations in 5 languages (English, German, French, Spanish, Japanese) accessible to patent examiners at EPO, USPTO, JPO, and other offices. TKDL successfully opposed 200+ patent applications globally by 2024. The CBD COP16 (Cali, Colombia, October 2024) progress on Digital Sequence Information (DSI) sharing is directly relevant to TKDL's scope — establishing obligations for benefit sharing when DSI from traditional knowledge databases is used for commercial research.
UPSC angle: GI tags (600+ products, India's first GI = Darjeeling Tea 2004, UP leads with 69 GIs), TKDL (0.34 million formulations, 5 languages, 200+ patent applications opposed), and CBD COP16 DSI benefit sharing linking to TKDL are Prelims and Mains GS-2/GS-3 content.
Pharmaceutical IPR — TRIPS Flexibilities and Section 3(d) Jurisprudence 2024
India's Section 3(d) of the Patents Act (preventing evergreening of pharmaceutical patents) faced renewed international scrutiny in 2024–2025 as the US maintained India on its "Priority Watch List" under the Special 301 Report — reflecting US pharmaceutical industry concerns about India's patent grant standards and data exclusivity refusal. India's position remains firm: Section 3(d) is TRIPS-compliant and essential for maintaining affordable medicine access, as affirmed by the Supreme Court in the Novartis (Glivec) case (2013).
Compulsory licensing gained renewed relevance in 2024 as India considered licensing provisions for cancer drugs. India's Patents Act (1970, amended 2005 for TRIPS compliance) allows compulsory licensing under Section 84 (public interest) and Section 92 (national emergency). The only compulsory licence granted so far was for Sorafenib (Nexavar, a cancer drug) in 2012 — a precedent India can invoke for high-cost patented drugs. The Doha Declaration (2001) unambiguously affirms that TRIPS shall not prevent measures to protect public health, providing India's legal cover for compulsory licensing in health emergencies.
UPSC angle: Section 3(d) anti-evergreening (Novartis/Glivec 2013 SC case), US Special 301 Report India pressure, Sorafenib compulsory licence (2012, only granted so far), Doha Declaration (2001), and data exclusivity refusal are Mains GS-2/GS-3 content on IPR and pharmaceutical access.
Key Terms for Quick Revision
| Term | Meaning |
|---|---|
| TRIPS | Trade-Related Aspects of Intellectual Property Rights — WTO agreement setting minimum IP standards |
| Section 3(d) | Anti-evergreening provision of India's Patents Act — prevents patenting of new forms unless enhanced therapeutic efficacy is shown |
| Compulsory licensing | Government-authorised production of a patented product without the patent holder's consent (Section 84, Patents Act) |
| GI tag | Geographical Indication — protects products with qualities attributable to their geographical origin |
| TKDL | Traditional Knowledge Digital Library — defensive database preventing biopiracy of India's traditional knowledge |
| Doha Declaration | 2001 WTO declaration affirming that TRIPS should not prevent measures to protect public health |
| Evergreening | Strategy to extend patent monopoly through minor modifications — prevented by Section 3(d) |
| Data exclusivity | Period during which regulators cannot use originator's clinical trial data for generic approval — India does NOT provide this |
| PVPFRA | Protection of Plant Varieties and Farmers' Rights Act, 2001 — protects both breeders' and farmers' rights |
| Biopiracy | Appropriation of traditional knowledge or biological resources without consent or benefit-sharing |
| CIPAM | Cell for IPR Promotion and Management — implements National IPR Policy under DPIIT |
| Article 31bis | TRIPS amendment (effective 2017) allowing export of generics under compulsory licence to countries without manufacturing capacity |
Exam Strategy
For Mains Answer Writing: IPR questions in GS-III often focus on the tension between innovation incentives and public access. The Novartis case, Nexavar compulsory licence, biopiracy cases, and India's pharmaceutical industry are your go-to examples. Always frame answers around India's position — use of TRIPS flexibilities, Section 3(d), refusal of data exclusivity — and explain why these positions serve both national interest and global public health. For GI tags, discuss their role in protecting rural livelihoods and traditional products, but also note challenges (weak enforcement, low awareness among artisans, limited commercial exploitation).
For Prelims: Key facts — Patents Act 1970 (amended 2005), patent term 20 years, Section 3(d) (anti-evergreening), Novartis case (2013), Nexavar compulsory licence (2012), TRIPS effective 1995, Doha Declaration 2001, first GI tag Darjeeling Tea (2004-05), 658 GI tags (2026), TKDL established 2001, National IPR Policy 2016, India 6th largest patent filer (2024), PVPFRA 2001.
